Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call

Celcuity (Nasdaq: CELC) will release its second quarter 2026 financial results after the market closes on Thursday, August 13, 2026.

Rhea-AI Summary

Celcuity (Nasdaq: CELC) will release its second quarter 2026 financial results after the market closes on Thursday, August 13, 2026. Management will host a webcast/teleconference at 4:30 p.m. Eastern Daylight Time the same day to discuss results and provide a corporate update.

Argus Aug 6 session 2 alerts

+0.36% close to close 1.99K volume Open Argus

Details

News Market Reaction – CELC

-12.0% Trough Tracked

$4.81B Market Cap

In the Aug 6 session, CELC gained 0.36%, reflecting a mild positive market reaction. Argus tracked a trough of -12.0% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The tag-specific history averaged -0.95% across five events, framing this scheduling notice against ...

Analysis

The tag-specific history averaged -0.95% across five events, framing this scheduling notice against a mildly negative prior record. The active S-3ASR includes a $400,000,000 ATM common-stock program, while recent insider activity was net selling.

Key Figures

Results Release Date: August 13, 2026 Webcast Time: 4:30 p.m. Eastern Daylight Time

Results Release Date

August 13, 2026

Second quarter 2026 financial results

Webcast Time

4:30 p.m. Eastern Daylight Time

Management webcast and teleconference on August 13, 2026

Previous Conferences,earnings date Reports

5 past events · Latest: May 07

Same Type 5 events

1. May 07

   Q1 earnings scheduling

   24h Move

   -6.3%

   Scheduled first-quarter results release and management webcast

2. Mar 18

   Q4 earnings scheduling

   24h Move

   -1.4%

   Scheduled fourth-quarter and full-year results release and webcast

3. Nov 05

   Q3 earnings scheduling

   24h Move

   +2.2%

   Scheduled third-quarter results release and management conference call

4. Aug 07

   Q2 earnings scheduling

   24h Move

   +0.1%

   Scheduled second-quarter results release and webcast conference call

5. May 07

   Q1 earnings scheduling

   24h Move

   +0.6%

   Scheduled first-quarter results release and management webcast

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

 MINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that it will release its financial results for the second quarter 2026 after the market closes on Thursday, August 13, 2026. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Daylight Time to discuss the results and provide a corporate update.

Webcast and Conference Call Information

To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this weblink: https://viavid.webcasts.com/starthere.jsp?ei=1767665&tp_key=7e57f2ab18. A replay of the webcast will be available on the Celcuity website following the live event.

About Celcuity

Celcuity is a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications. The company's first FDA-approved product is REVTORPYK™ (gedatolisib), a pan-PI3K and mTORC1/2 inhibitor that comprehensively blocks the PI3K/AKT/mTOR (“PAM”) pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT or mTORC1, alone or together.

A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- locally advanced or metastatic breast cancer (“ABC”), supported FDA approval of REVTORPYK for use in patients without a PIK3CA mutation detected. Results for the PIK3CA mutant cohort of VIKTORIA-1 were presented during an oral presentation at the American Society for Clinical Oncology (ASCO) in June 2026.

VIKTORIA-2 is an ongoing Phase 3 clinical trial incorporating two independent studies, Study 1 and Study 2, in two separate cohorts of patients with ABC who are treatment-naive in the advanced setting. Study 1 is evaluating gedatolisib plus palbociclib plus fulvestrant as first-line treatment for patients with endocrine-resistant HR+/HER2- ABC. Study 2 is evaluating gedatolisib plus palbociclib plus letrozole as first-line treatment for patients with endocrine- sensitive HR+/HER2- ABC. A Phase 1/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration-resistant prostate cancer, is ongoing.

More detailed information about Celcuity’s active clinical trials can be found at ClinicalTrials.gov. Celcuity is headquartered in Minneapolis, Minnesota. Further information about Celcuity and its products, including important safety information and full prescribing information can be found at www.celcuity.com. Follow us on LinkedIn and X.

Contacts: 

Celcuity Inc. 
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com  
(763) 392-0123  
Jodi Sievers, jsievers@celcuity.com
(415) 494-9924

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Celcuity (CELC) report its Q2 2026 financial results?

Celcuity will report its Q2 2026 financial results on Thursday, August 13, 2026, after the market closes. According to Celcuity, the release will be followed by a webcast and teleconference that same afternoon.

What time is Celcuity's Q2 2026 earnings webcast and conference call?

Celcuity's Q2 2026 webcast and conference call is scheduled for 4:30 p.m. Eastern Daylight Time on August 13, 2026. According to Celcuity, management will discuss financial results and provide a corporate update during the event.

How can investors join Celcuity's Q2 2026 CELC earnings conference call?

Investors can join the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international participants. According to Celcuity, these numbers provide direct access to the Q2 2026 teleconference.

Where can I access the live webcast for Celcuity's Q2 2026 results?

The live webcast for Celcuity's Q2 2026 results can be accessed at https://viavid.webcasts.com/starthere.jsp?ei=1767665&tp_key=7e57f2ab18. According to Celcuity, this link will host the real-time presentation and discussion.

Will a replay be available for Celcuity's Q2 2026 CELC earnings webcast?

Yes, a replay of Celcuity's Q2 2026 webcast will be available on the company's website after the live event. According to Celcuity, investors can access the recording for later listening.

What will Celcuity management cover during the Q2 2026 earnings call?

Celcuity management will discuss second quarter 2026 financial results and provide a corporate update. According to Celcuity, the webcast and teleconference are intended to review performance and recent company developments.